Sahakian, Eva

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research

Immune cells in cancerImmunotherapy and Immune Responses

Cited by 500

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., et al. (2019) · Scientific Reports

Cancer Immunotherapy and BiomarkersHistone Deacetylase Inhibitors Research

Cited by 170

A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs

Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology

Histone Deacetylase Inhibitors ResearchT-cell and B-cell Immunology

Cited by 106

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Yue, L., Sharma, V., Horvat, N. P., Akuffo, A. A., Beatty, M. S., Murdun, C., Colin, C., Billington, J. M. R., Goodheart, W. E., Sahakian, E., et al. (2020) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentHistone Deacetylase Inhibitors Research

Cited by 67

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

Mostofa, A., Distler, A., Meads, M. B., Sahakian, E., Powers, J. J., Achille, A., Noyes, D., Wright, G., Fang, B., Izumi, V., et al. (2021) · JCI Insight

Multiple Myeloma Research and TreatmentsHistone Deacetylase Inhibitors Research

Cited by 27